Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) YoY EPS Growth : 72.58% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Biocytogen Pharmaceuticals (Beijing) Co's YoY EPS Growth for the quarter that ended in Jun. 2024 was 72.58%.

Biocytogen Pharmaceuticals (Beijing) Co's Earnings per Share (Diluted) for the six months ended in Jun. 2024 was €-0.02.

Biocytogen Pharmaceuticals (Beijing) Co YoY EPS Growth Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co YoY EPS Growth Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

YoY EPS Growth

-40.44

-12.04

42.52

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
YoY EPS Growth	Get a 7-Day Free Trial			-19.75	-7.69	36.08	44.64	72.58

Biocytogen Pharmaceuticals (Beijing) Co YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Biocytogen Pharmaceuticals (Beijing) Co's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EPS Growth (A: Dec. 2023 )
=	(Earnings per Share (Diluted) (A: Dec. 2023 )	-	Earnings per Share (Diluted) (A: Dec. 2022 ))	/	\| Earnings per Share (Diluted) (A: Dec. 2022 ) \|
=	(-0.123	-	-0.214)	/	\| -0.214 \|
=	42.52 %

Biocytogen Pharmaceuticals (Beijing) Co's YoY EPS Growth for the quarter that ended in Jun. 2024 is calculated as:

	YoY EPS Growth (Q: Jun. 2024 )
=	(Earnings per Share (Diluted) (Q: Jun. 2024 )	-	Earnings per Share (Diluted) (Q: Jun. 2023 ))	/	\| Earnings per Share (Diluted) (Q: Jun. 2023 )) \|
=	(-0.017	-	-0.062)	/	\| -0.062 \|
=	72.58 %

Biocytogen Pharmaceuticals (Beijing) Co YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » YoY EPS Growth

Comparable Companies

Traded in Other Exchanges

02315:Hong Kong

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines